Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Researcher taking shot at flu vaccine that’s more effective, easier to make

By Drug Discovery Trends Editor | February 7, 2013

Purdue University professor Suresh Mittal removes a sample of cells used to grow a viral vector-based influenza vaccine with graduate students (from left) Sai Vemula, Ahmed Hassan and Omar Amen. Mittal and his students are working on a flu vaccine that offers broad protection against most strains of the virus. Purdue University photo/Jane KovachThis year’s vaccine is 62% effective or “moderately” effective against the current flu strains, according to early estimates from the Centers for Disease Control and Prevention. Flu-related deaths this season have reached an epidemic level and include 45 children, according to the most recent report.

Suresh Mittal, a professor of comparative pathobiology in Purdue’s College of Veterinary Medicine, is applying a method he developed for an avian flu vaccine to create a more universal seasonal flu vaccine. The vaccine’s protection could persist through different strains and mutations of the influenza virus and would not be dependent on accurate predictions of the strains expected each season, he said.

“This method allows us to create a vaccine that targets core parts of the influenza virus that are found across all strains and don’t mutate or change quickly,” Mittal said. “It also allows us to target multiple parts of the virus, so that even if the virus adapts to one line of attack, there are others that will still work to prevent the illness.”

The method uses a harmless adenovirus as a vector to deliver influenza virus genes into the body where they create a two-fold immune response of antibody and cell-based protection. The adenovirus releases the genes inside the host cells, which then create proteins that lead to the creation of antibodies and special T-cells primed to kill influenza virus and any cells infected by it.

“This method works beyond that of the current vaccine, in which the body responds to inactivated virus proteins injected into a muscle,” Mittal said. “Getting the influenza virus genes inside the cells better mimics an infection and leads to a more powerful and multifaceted immune response, so we are better prepared to fend off a true infection.”

Any genes important to influenza virus protection can be incorporated into the adenovirus vector, and it can be designed to expose the immune system to components from both the surface and deep within the virus. In this way the immune system can be primed to recognize portions of the virus that are the same across all strains and those that are more difficult for the virus to change as it adapts to the immune system attack, he said.

The new vaccine also has manufacturing advantages over current methods because the vector is easily grown in cell culture. The current flu vaccine depends on the growth of influenza viruses in chicken eggs.

“Sometimes the virus strains selected for the year’s vaccine do not grow well in an egg and that can lead to delays or shortages of the vaccine,” Mittal said. “The new method depends only on the growth of the virus vector, which we know how to grow quite well. The influenza strains we select to include have no effect on the growth or the amount of vaccine that can be made.”
Mittal said vaccination is critical to save lives.

“We don’t think of the flu as a killer, but it kills around 35,000 people each year,” he said. “Even when the flu vaccine isn’t a perfect match, it still offers the best protection. It also is important to get vaccinated to help prevent the spread of the virus to those who are too young or too sick to be vaccinated themselves.”

Source: Purdue University


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50